1. Show article details.

    EU mergers and takeovers (July 30)

    Reuters – 2:01 PM ET 07/30/2015

    The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS. -- Investment fund Apollo Management L.P. to acquire Saint-Gobain Emballage, Saint Gobain Vicasa S.A., Saint Gobain Vidros and Obale, with the group known as Verallia. -- U.S. drugmaker Mylan to acquire U.S. peer Perrigo (PRGO). NEW LISTINGS.

  2. Show article details.

    Teva Profit Falls on Legal Expenses

    DJ Business News – 9:45 AM ET 07/30/2015

    Teva Pharmaceuticals Industries Ltd. said profit declined in its latest quarter as the generic drug maker paid more in expenses related to legal settlements and restructuring, though profit still beat Wall Street expectations. The company also said it was raising its full-year guidance for per-share earnings to a range of $5.15 to $5.40 from its previous range of $5.05 to $5.35. Teva recently said it would buy the generics business of Allergan PLC (AGN) for about $40 billion, a move...

  3. Show article details.

    Mylan Gets European Regulator's Approval for Perrigo Deal

    DJ Business News – 8:15 AM ET 07/29/2015

    Mylan NV (MYL) said it has gotten regulatory approval from the European Commission to move ahead with its planned purchase of Perrigo Co. (PRGO), the latest advancement in a saga of recent drug maker consolidation. Mylan had proposed in April to buy rival Perrigo (PRGO) for $28.9 billion, as it tried to stay ahead of the frantic deal making that has been reshaping the drug industry. A combination of Mylan and Perrigo (PRGO) would create one of the world's top sellers of low-price medicines, with more than $15...

  4. Show article details.

    Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo

    PR Newswire – 7:00 AM ET 07/29/2015

    HERTFORDSHIRE, England and PITTSBURGH, July 29, 2015 Mylan N.V. (MYL) today announced that it received regulatory clearance from the European Commission under the European Union Merger Regulation for its proposed acquisition of Perrigo Company plc.

  5. Show article details.

    EU clears acquisition of Perrigo by Mylan

    Reuters – 6:16 AM ET 07/29/2015

    The European Commission said on Wednesday it had cleared generic drug maker Mylan's planned takeover of Ireland-based Perrigo Co. The Commission said in a statement that the proposed acquisition would not raise competition concerns, because the parties' activities are largely complementary, Mylan being one of the main European producers of prescribed generic drugs and Perrigo (PRGO) specialised in sel...

  6. Show article details.

    10 S&P 500 stocks with the biggest declines over the past week

    MarketWatch – 8:16 AM ET 07/28/2015

    Weak oil and copper prices and disappointing earnings have taken their toll. It appears we're set up for another painful week for U.S. stocks. Investors may have been surprised to wake up to an 8.5% decline in the Shanghai Composite Index on Monday, its worst one-day drop in eight years, but a slide in oil and other commodities also is taking a heavy toll.

  7. Show article details.

    Mylan independence from Teva's embrace comes with a price

    Reuters – 7:00 AM ET 07/28/2015

    Generic drugmaker Mylan NV (MYL) won a reprieve on Monday from its unwanted suitor, Teva Pharmaceutical Industries (TEVA), but now faces an uphill battle to make its own acquisition as its biggest rival just got bigger. Teva announced a $40.5 billion deal for the generic assets of Allergan Plc (AGN) after an unsuccessful three-month attempt to bring Mylan to the table.

  8. Show article details.

    PRESS DIGEST- Wall Street Journal - July 28

    Reuters – 12:48 AM ET 07/28/2015

    The following are the top stories in the Wall Street Journal. * The Obama administration plans to restore federal funding for prison inmates to take college courses, a potentially controversial move that comes amid a broader push to overhaul the criminal justice system.

  9. Show article details.

    PRESS DIGEST- New York Times business news - July 28

    Reuters – 12:31 AM ET 07/28/2015

    The following are the top stories on the New York Times business pages. * Teva Pharmaceutical Industries (TEVA) has found a neat exit from its Mylan NV (MYL) mess. * Fiat Chrysler Automobiles (FCAU) could pay up to $105 million in addition to giving authority to an independent monitor to oversee safety operations, buying back defective vehicles and paying consumers to participate in a Jeep recall.

  10. Show article details.

    Mylan independence from Teva's embrace comes with a price

    Reuters – 6:11 PM ET 07/27/2015

    Generic drugmaker Mylan NV (MYL) won a reprieve on Monday from its unwanted suitor, Teva Pharmaceutical Industries (TEVA), but now faces an uphill battle to make its own acquisition as its biggest rival just got bigger. Teva announced a $40.5 billion deal for the generic assets of Allergan Plc (AGN) after an unsuccessful three-month attempt to bring Mylan to the table.

  11. Show article details.

    Mylan's Leverage to Resist Teva Deal Reveals Shift in Rules

    DJ Business News – 4:54 PM ET 07/27/2015

    In May, Mylan NV's (MYL) executive team met with investors in a Manhattan conference room. As shareholders complained about the drug maker's resistance to a $40 billion takeover proposal from Teva Pharmaceutical Industries Ltd. (TEVA), Executive Chairman Robert Coury leaned across the table. "This is a stakeholder company, not a shareholder company," he said, in language laced with expletives, according to multiple attendees, meaning his constituents went beyond investors.

  12. Show article details.

    Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders

    PR Newswire – 3:58 PM ET 07/27/2015

    HERTFORDSHIRE, England and PITTSBURGH, July 27, 2015 Mylan N.V. (MYL) today announced that it will hold its extraordinary general meeting of shareholders in connection with its proposed acquisition of Perrigo Company plc (PRGO) at the Okura Hotel Amsterdam on Friday, Aug. 28, 2015 at 1 p.m. Central European Time.

  13. Show article details.

    BRIEF-Teva says Allergan generic drug business was first choice

    Reuters – 8:58 AM ET 07/27/2015

    Teva comments on Allergan (AGN) generic drug acquisition: * Teva CEO says Allergan's (AGN) generic drug business was preferred target in 2014. * Allergan (AGN) last year was not willing to sell so Teva made bid for Mylan - Teva CEO. * Teva approached Allergan (AGN) again in last 2-1/2 weeks -Teva CEO. * Allergan (AGN) deal expected to result in fewer antitrust-related asset sales than Mylan deal would have.

  14. Show article details.

    Teva to Buy Allergan Generics for $40.5 Billion -- 6th Update

    DJ Business News – 8:46 AM ET 07/27/2015

    By Jonathan D. Rockoff, Dana Mattioli and Liz Hoffman. Teva Pharmaceutical Industries Ltd. (TEVA) on Monday agreed to buy Allergan PLC's (AGN) generics unit for $40.5 billion in cash and stock, in a deal that will vault the Israeli company into the top ranks of global drug makers. Teva said Allergan (AGN) would receive $33.75 billion in cash and Teva shares valued at $6.75 billion, giving it a 10% stake in Teva.

  15. Show article details.

    Teva to buy Allergan generics for $40.5 billion

    MarketWatch – 7:57 AM ET 07/27/2015

    By Jonathan D. Rockoff, Dana Mattioli and Liz Hoffman. Deal puts Teva among biggest drug makers, enables it to drop bid for Mylan. Teva Pharmaceutical Industries Ltd. (TEVA) on Monday agreed to buy Allergan PLC's (AGN) generics unit for $40.5 billion in cash and stock, in a deal that will vault the Israeli company into the top ranks of global drug makers.

  16. Show article details.

    Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit

    PR Newswire – 6:42 AM ET 07/27/2015

    HERTFORDSHIRE, England and PITTSBURGH, July 27, 2015 Mylan N.V. (MYL) today issued the following statement regarding Teva's announcement of its entry into an agreement to acquire Allergan's Generic Drug Unit and its withdrawal of its unsolicited expression of interest to acquire Mylan.

  17. Show article details.

    Teva to Buy Allergan Generics for $40.5 Billion

    DJ Business News – 6:15 AM ET 07/27/2015

    Teva Pharmaceutical Industries Ltd. (TEVA) on Monday agreed to buy Allergan PLC's (AGN) generics unit for $40.5 billion in cash and stock, in a deal that will vault the Israeli company into the top ranks of global drug makers. Teva said Allergan (AGN) would receive $33.75 billion in cash and Teva shares valued at $6.75 billion, giving it a 10% stake in Teva. The deal, the latest in a wave of consolidation in the drug industry, combines Teva, the world's largest generic-drug company by sales, with the...

  18. Show article details.

    Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid

    Reuters – 5:48 AM ET 07/27/2015

    Israel’s Teva Pharmaceutical Industries (TEVA) will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan (AGN) to focus on branded drugs, paying down debt and potential "transformational" acquisitions.

  19. Show article details.

    Teva buying Allergan Generics for $40.5 billion; drops Mylan bid

    MarketWatch – 5:22 AM ET 07/27/2015

    Israeli drug maker Teva Pharmaceutical Industries Ltd. (TEVA) said on Monday it has agreed with Allergan PLC (AGN) to take over Allergan Generics for $40.5 billion. Teva is already the world's biggest seller of generic medicines with a market value of about $60 billion and the acquisition "reinforces" its strategy in the generics industry, the company said. The Israeli drug maker had also been looking into buying generic-drug company Mylan NV (MYL), but said on Monday after the Allergan...

  20. Show article details.

    Teva Withdraws Proposal to Acquire Mylan

    Business Wire – 4:31 AM ET 07/27/2015

    Teva Pharmaceutical Industries Ltd. (TEVA) today announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan N.V. (MYL) and Teva does not intend to continue to pursue a transaction with Mylan at this time.

Page:

Today's and Upcoming Events

  • Aug
    6

    MYL to announce Q2 earnings Before Market (Confirmed)

  • Aug
    6

    MYL Earnings Conference Call at 10:00 AM Listen

  • Aug
    28

    Shareholders Meeting

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.